XNYS · Medical Devices
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$107.32-0.93%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
62/100
Positive
Score components
TickerWhale View
Zimmer Biomet Holdings scores 62 out of 100 overall, which we rate positive. Technical is its strongest area and Risk its weakest.
What helps
- Technical
- Valuation
- Sentiment Signal
What to watch
- Quality & growth
- Risk
Quality & growth
30%41Weak
- Revenue growth 8.6%
- EPS growth 0.0%
Valuation
25%80Strong
- P/E 25.6
- EV/Sales 3.3
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
#456 by market cap in our coverage · ~17,000 employees · Listed 2001-08-07 · www.zimmerbiomet.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#35 / 139sector rank by TickerWhale Score
TickerWhale Score 62 vs sector average 54.6 (+7.4)
Revenue growth (industry)Top 61%
Gross margin (industry)Top 28%
Return on equity (industry)Top 78%
P/E (industry)Cheaper than 80%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
91/100Strong vs universe
Ranks 91st of 100 covered names on our technical composite — the composite itself scores 81/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Buy
6 buy · 0 sell · 2 neutral of 8 votes
TickerWhale rates ZBH's technical setup strong — 91st percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+16.3%
- vs 50-day+12.5%
Momentum
Constructive
- RSI (14)65 · neutral
- Stochasticbuy
- CCIbuy
- Williams %Rneutral
Trend
Constructive
- ADX (14) trend strength28· trending
- MACD (12,26,9)buy(histogram 1.209)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 5 buy · 0 sell · 2 neutral.
Result — 6 buy vs 0 sell of 8 votes = Strong Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)25.6
- P/S (TTM)2.4
- P/B1.6
- EV/EBITDA—
- EV/Sales3.3
- PEG—
Profitability & returns
- Gross margin69.9%
- Net margin9.5%
- ROE6.4%
- Debt/Equity0.59
Growth
- Revenue growth (YoY)8.6%
- EPS growth (YoY)0.0%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $20.7B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ZBHCurrentZimmer Biomet Holdings | 62 | 81 | 25.6 | — | 1.6 | 3.3 | $107.32 | -0.93% | +8.6% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.